HER2-POSITIVE PUBLICATIONS & ABSTRACTS
HER2-positive Data
Evidence / HER2-positive
HER2-low in the FLEX Study, Sivapiragasam et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-02 Authors: Sivapiragasam et al.
Read MoreTRAIN 2 Trial: BluePrint predicts response to neoadjuvant pertuzumab in HER2-positive
Breast Cancer Research 25, Article Number: 71 (2023) Authors: Liefaard et al.
Read MoreImpact of race on BluePrint genomic subtyping in HER2+ breast cancer
Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.
Read MoreASCO 2020: HER2 Reclassification
PUBLICATION: ASCO 2020 AUTHORS: Adam Brufsky, Jennifer A. Crozier, Paul J. Chuba, Sung Ho Lee, Andrea Menicucci, Heather M. Kling, Erin Yoder, William Audeh, FLEX Investigators' Group SUMMARY: Biological heterogeneity of HER2 positive breast cancers is supported by a modest benefit of HER2- targeted therapies reported in the APHINITY and Read More
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van โt Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrintยฎ Read More
Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature
PUBLICATION: Br J Cancer. 2010 Dec 7; 103(12): 1788โ1793. Published online 2010 Nov 16. doi: 10.1038/sj.bjc.6605916. AUTHORS: M. Knauer, F. Cardoso, J. Wesseling, P.L. Bedard, S.C. Linn, E.J.T. Rutgers, and L.J. van't Veer Background: Overexpression of HER-2 is observed in 15โ25% of breast cancers, and is associated with increased risk Read More